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Abstract: The regeneration of articular cartilage damaged due to trauma and posttraumatic 
osteoarthritis is an unmet medical need. Current approaches to regeneration and tissue 
engineering of articular cartilage include the use of chondrocytes, stem cells, scaffolds and 
signals, including morphogens and growth factors. Stem cells, as a source of cells for 
articular cartilage regeneration, are a critical factor for articular cartilage regeneration. This 
is because articular cartilage tissue has a low cell turnover and does not heal spontaneously. 
Adult stem cells have been isolated from various tissues, such as bone marrow, adipose, 
synovial tissue, muscle and periosteum. Signals of the transforming growth factor beta 
superfamily play critical roles in chondrogenesis. However, adult stem cells derived from 
various tissues tend to differ in their chondrogenic potential. Pluripotent stem cells have 
unlimited proliferative capacity compared to adult stem cells. Chondrogenesis from 
embryonic stem (ES) cells has been studied for more than a decade. However, establishment 
of ES cells requires embryos and leads to ethical issues for clinical applications. Induced 
pluripotent stem (iPS) cells are generated by cellular reprogramming of adult cells by 
transcription factors. Although iPS cells have chondrogenic potential, optimization, 
generation and differentiation toward articular chondrocytes are currently under intense 
investigation. 








Articular cartilage (AC) is an avascular tissue, which consists of abundant extracellular matrix. AC 
does not heal spontaneously under physiological circumstances due to innate avascularity, low 
cellularity and low cell turnover [1] that can lead to progression of osteoarthritis (OA). OA is the most 
common musculoskeletal disease in the elderly and could become the fourth leading cause of disability 
by the year 2020 [2]. So far, there are limited options for OA treatment, such as pharmaceutical 
interventions and joint replacement surgery [3]. In terms of AC regeneration, many procedures, such as 
subchondral drilling, abrasion arthroplasty, osteochondral grafts and transplantation of mesenchymal 
stem cells (MSCs) or chondrocytes, have been developed [4?8]. Differentiation toward cartilage was 
induced by morphogens, such as transforming growth factor (TGF)-? superfamily and members of the 
bone morphogenetic protein (BMP) family. The resulting differentiated chondrocytes expressed 
cartilage specific markers, such as type II collagen and Aggrecan. Currently, autologous chondrocyte 
transplantation is widely used for AC regeneration in clinic. However, donor site morbidity is a 
challenge [9]. Use of stem cells in combination with growth factors and scaffolds is another option for 
AC regeneration [1]. In the present review, we discuss chondrogenesis using stem cells and 
morphogenetic proteins for potential applications in regeneration of AC. 
2. Stem Cells and Chondrogenesis 
2.1. Adult Stem Cells  
Stem cells are mainly classified into two kinds of cells: somatic stem cells and pluripotent stem cells. 
Somatic stem cells reside in various tissues or organs and have shown multipotency to regenerate 
damaged tissues [10]. MSCs have been studied intensively in the field of orthopedic research [11]. 
These cells are characterized as plastic-adherent, fibroblastic spindle-shaped, multipotent stem cells and 
can differentiate into bone, cartilage and adipose tissue [12]. Also, MSCs are distinguished from 
hematopoietic cells by being negative for hematopoietic markers such as CD14, CD34 and CD45, but 
expressing CD29, CD44, CD73 (SH3 and 4), CD90, CD105 (SH2) and CD166 [12,13]. During in vitro 
culture conditions, MSCs are known to change their surface marker expression [14]. MSCs have been 
isolated from various tissues, such as bone marrow, adipose, synovial tissue, muscle and  
periosteum [15]. These cell populations are heterogeneous and not clonal populations [14], and MSCs 
derived from various tissues tend to differ in their expansion capacity and differentiation ability to 
chondrocytes [16] (Table 1). 
Fetal bovine serum (FBS) is widely added to culture medium to expand the populations [17]. 
However, the potential risk of zoonotic infection or immunogenic reaction is an ever-present danger  
and a drawback. To reduce these risks, the use of serum free MSC culture media has been  
developed [18,19].  
2.1.1. Bone Marrow-derived MSCs (BMMSCs) 
In the 1960s, the evidence that bone marrow (BM) includes mesenchymal cells that can generate 
connective tissue-forming cells was provided by the pioneering work of Friedenstein [20]. A number of 
Cells 2012, 1 996 
 
 
investigators extended these observations and confirmed that the cells identified by Frirdenstein were 
multipotent and could differentiate into osteoblasts, chondrocytes and adipocytes [17,21?24]. In 1999, 
Pittenger et al. demonstrated that individual human MSCs, which form colonies during their expansion, 
could retain their multilineage potential [12].The standard methods for the isolation of BMMSCs is 
density gradient centrifugation method [17]. Using this method, nucleated cells are separated from 
nonnucleated red blood cells, and thereafter, MSCs are allowed to attach to a plastic culture dish [24]. It 
is noteworthy that BMMSCs are most widely studied to induce chondrogenesis in three-dimensional 
cultures. To date, the most promising growth factors for chondrogenesis of BMMSCs are TGF-? 
superfamily, such as TGF-??? -?? and -??, and members of the BMP family, such as BMP-2,  
-6 or -7 [12,25?34]. While TGF-??? ???? ????t used to enhance chondrogenesis [25,26], Barry et al. 
reported that the presence of TGF-??????-?? could also induce chondrogenic differentiation [28]. When 
they were used in combination of BMP-2 or -6 with TGF-??, higher collagen II expression was observed 
than using a single growth factor [31,32]. Although BMMSCs are widely used clinically as a stem cell 
source [35,36], aspiration of BM is an invasive and painful procedure, often requiring anesthesia and 
often with attendant morbidity [37]. 
2.1.2. Adipose Tissue-Derived MSCs (ATMSCs) 
In 2001, Zuk et al. identified ATMSCs from lipoaspirates, which have multilineage potential to 
differentiate into adipogenic, chondrogenic, myogenic and osteogenic cells [38]. Following studies also 
showed the multipotentiality of ATMSCs [39,40]. However, recent studies demonstrated that ATMSCs 
do not produce results comparable with those of BMMSCs when treated with a variety of growth factors, 
including TGF-????-????-???????-2, -6, -7 or IGF-1 [38,41?44]. While a combination of BMP-2 and 
TGF-???[45,46] or a combination of BMP-7 and TGF-???[44] amplified the chondrogenic potential by 
more than a single factor alone, combinations of BMP-2, -4 or -7 with TGF-???????????????????????????
effects [47]. Moreover, several reports showed that the chondrogenic potential of ATMSCs is not as 
extensive as that of BMSCs [33,45,48,49]. Despite their inferior chondrogenic potential, interest has 
increased in the use of ATMSCs, because they are relatively abundant and harvesting techniques of fat 
tissue might be less invasive than that of BM [33]. 
Table1. In vitro chondrogenesis using adult human stem cells. 
Tissue Source Isolation Method Culture System Growth Factors 
Bone Marrow [26] Precoll  Pellet TGF-???  
Bone Marrow [12,27] Precoll  Pellet TGF-?? 
Bone Marrow [28] Precoll  Pellet TGF-???????? 
Bone Marrow [29] ?????? ????????????? Alginate beads BMP-2, GDF-2 
Bone Marrow [30,34] Ficoll Pellet TGF-???????-6 
Bone Marrow [31] Precoll  Pellet TGF-???????-2 
Bone Marrow [32] N/A Pellet TGF-???????-2, IGF-1 
Adipose [38] ?????????????????????????? Micromass TGF-???  
Adipose [41] ?????????????????????????? Alginate Beads TGF-?? 
Adipose [42] ?????????????????????????? Pellet TGF-???????-1 
Adipose [43] ?????????????????????????? Alginate Beads TGF-??????????-6, IGF-1 
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Table 1. Cont. 
Tissue Source Isolation Method Culture System Growth Factors 
Adipose [49] ?????????????????????cells Pellet TGF-?? 
Adipose [44] ?????????????????????????? Pellet TGF-???????-2, 6, 7 
Syovium [50] ?????????????????????????? Micromass TGF-?? 
Syovium [16] ?????????????????????????? Pellet, collagen gel TGF-???????-2 
Synovium [55] ?????????????????????????? Pellet 
TGF-???????-2, IGF-1, 
FGF-2, Retinoic Acid 
Periosteum [50] ?????????????????????????? Micromass 
TGF-????????????????
GDF-5 
Periosteum [16] ?????????????????????????? Pellet TGF-???????-2 
Muscle [63] ?????????????????cells Pellet TGF-?? 
Muscle [16] ?????????????????????????? Pellet TGF-???????-2 
Muscle [64] CD56+34+144+ cells Pellet TGF-???????-4 
Traumatized Muscle [65] ?????????????????????????? Pellet TGF-?? 
2.1.3. Synovium-Derived MSCs (SMSCs) 
MSCs from human synovial membrane tissue, known as synovial-derived MSCs, were successfully 
isolated by De Bari et al. in 2001 [50]. Synovial membrane contains two types of cells: macrophage-like 
cells and fibroblast-like cells; the fibroblast-like cells are believed to be the source of MSCs [51]. 
Chondrogenesis from SMSCs has been reported by using growth factors such as TGF-???? -?? and 
BMP-2, -7, similar to other adult stem cells [16,52?54]. And combination of BMP-2 and TGF-???
showed higher chondrogenic potential [55]. The fact that both synovium and cartilage are proven to 
originate from a common pool of progenitor cells [56] suggests that SMSCs may already possess a 
strong bias toward the production of cartilage tissue. In fact, several studies showed that SMSCs have 
greater chondrogenic potential than BMMSCs [16,51,57]. Also, it has been reported that multipotent 
capacity of SMSCs is not influenced by donor age or cell passages, and SMSCs have less senescence and 
great proliferation ability [16,50]. Clinically, arthroscopic surgery is necessary to obtain synovium, but 
the procedure is less invasive than harvesting BM. Thus, SMSCs could be an attractive and readily 
accessible cell source for cartilage regeneration. 
2.1.4. Periosteum-Derived MSCs (PMSCs) 
Periosteum is at the boundary between the bone and the surrounding soft tissues and contains 
multiple cell types that are thought to function as progenitor cells. Nakahara et al. reported in vivo 
chondrogenic potential of human PMSCs in 1991 [58]. It was not until 2006 that mesenchymal 
multipotency of adult human periosteal cells was demonstrated by single-cell lineage analysis [59]. They 
reported that TGF-?? induced chondrogenesis consistently, but BMP-2, -4, -7 and GDF-5 did not. In the 
comparative analysis, the chondrogenic ability of PMSCs by treatment with TGF-??? ???????-2 was 
equal to that of BMMSCs [16]. However, harvesting periosteum is invasive and retains a high probability 
of donor-site morbidity. 
  
Cells 2012, 1 998 
 
 
2.1.5. Muscle-Derived Stem Cells (MDSCs) 
The existence of progenitor cells in the skeletal muscle has been long postulated for a long time, 
based on the evidence that bone and cartilage formation was observed within the muscle tissue after 
implantation of demineralized bone matrix [60,61]. The origin of MDSC is thought to be a 
subpopulation of endothelial cells or pericytes associated with muscle capillaries [62]. Human MDSCs 
with multilineage potential were first reported by Mastrogiacomo in 2005 [63]. Treatment with TGF-???
showed chondrogenic differentiation of human MDSCs [63]. Afterward, several groups reported the 
chondrogenic differentiation by utilizing growth factors including TGF-????-?? or BMP-2, -4 [16,63,64]. 
Chondrogenic potential of MDSCs is controversial compared to BMMSCs. Whereas MDSCs from 
normal muscle showed lower chondrogenic potential compared to other MSCs [16], traumatized muscle 
derived MSCs exhibited similar phenotype and chondrogenic potential [65]. 
2.2. Pluripotent Stem Cells 
The heterogeneity of MSC populations isolated from different tissues makes it difficult to 
determine the most appropriate tissue source for MSCs [66]. Somatic stem cells have limited in vitro 
proliferative potential, and their proliferative capacity and synthetic capacity declines with  
age [67,68], which restricts the use of MSCs in clinical application. On the other hand, pluripotent stem 
cells show unlimited proliferative capacity and are attractive for researchers as a better source of stem 
cells for tissue regeneration [2,66] (Table 2). 
Table 2. In vitro chondrogenesis using human ES and iPScells. 
Tissue Source (Cell line ) 
MSC differentiation 
Method 
Culture System Growth Factors 












ES cell (BG02) [79] 
ES colony (cultured with 




ES cell (H1, H9) [115] 
EB 10days??????????????????
with, w/o EB digestion 
Micromass BMP-2 
ES cell (BG01, 02) [84] 
EB 5days??????????????????
w/o EB digestion 
Self assembly TGF-?? 
ES cell (BG01V) [116] EB 21days ???????????????? Self assembly TGF-??????????-2, IGF-1 
ES cell (H9) [85] 
EB 5days?????????????????
plating 
ES colony digestion & plating 
Micromass TGF-???????????? 
ES cell (H9) [75] 
ES colony digestion & 
plating 
Pellet TGF-???????-7 
ES cell (SA167, AS034, 
AS034.1) [80] 
ES colony (cultured with 
chondrocyte ) derived cells 
Pellet, Agarose gel TGF-?? 
ES cell (BG01V) [88] 
EB 21days ????????????????
self assembly 
Self assembly in 
Agarose gel 
TGF-?? 
Cells 2012, 1 999 
 
 
Table 2. Cont. 
Tissue Source (Cell line ) 
MSC differentiation 
Method 
Culture System Growth Factors 






ES cell (H9) [77] 
EB 5days?????????????????
plating 





ES cell (H9, BG01V) 
[117] 
EB 7, 21, 42days?????
digestion & self assembly 
Self assembly in 
Agarose gel 
None 
ES cell (H9) [81] EB 21days 
EB in Agarose gel 
co-culture with 
chondrocyte 
TGF-???????-2, 4, 6, 
PDGFbb, Shh 
ES cell (H9) [86] 
EB 21days in normoxia / 
hypoxia 
Agarose gel None 
ES cell (H9) [118] 
Co-culture with mouse stoma 
cell followed by 
CD34+/CD73- sorting 
Pellet TGF-?? 
ES cell (HUES3, 
ZJUhES-1) [119] 
ES colony dissociation with 
Y-27632 (ROCK inhibitor) 
Monolayer TGF-?? 





TGF-???????-2, 7, GDF-5, 
IGF-1 
ES cell (HUES1,7,8) [76] 
Direct differentiation from 
ES colony 
Monolayer 
Wnt3a, ActivinA, FGF-2, 
BMP-4, Follostatin, GDF-5, 
Neurotrophin-4 
iPS (fibroblast) [120] 
EB 7days??????????????????
w/o EB digestion 
Pellet TGF-?? 
iPS (HDFa-YK26) [114] 
iPS colony dissociation with 
Y-27632 (ROCK inhibitor) 
Pellet TGF-?? 
iPS (OA chondrocyte) [2] 
OA chondrocyte derived iPS 
transfected with TGF-?? 




iPS (OA synovial cell) 
[66] 
EB 5days??????????????????
with EB digestion 
Pellet, Agarose gel BMP-2 
2.2.1. Embryonic Stem (ES) Cells 
The most well-known pluripotent stem cells are ES cells first reported in the mouse in 1981 and in 
humans in 1998 [69?71]. ES cells are derived from the inner cell mass of a blastocyst. The ability of ES 
cells to form cartilage is well known, because they can form teratoma containing cartilage when they are 
transplanted into nude mice [72]. However, the in vitro chondrogenesis condition is yet to be 
determined. As the first step towards differentiation, most ES cell culture protocols follow embryoid 
bodies (EBs) formation [72]. EBs are free-floating aggregates of ES cells and can differentiate at random 
into lineages of all three germ layers?endoderm, mesoderm and ectoderm. These EBs, or single cells 
derived from these EBs, are used in the subsequent differentiation steps. In the first report of in vitro 
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chondrogenesis from mouse ES cells, an EB culture system was used. The cartilage like regions 
displayed various stages of chondrogenesis [73]. Though EB method is convenient for inducing 
differentiation by the interaction of the cells within the EBs, this method possesses certain limitations. 
First, it is difficult to dissect the differentiation mechanisms by using single cells. In addition, it is difficult to 
control the size or number of EBs [74]. Meanwhile, chondrogenesis without EB formation has been reported 
using co-culture methods or several combinations of growth factors [75?77]. Vats et al. first reported 
chondrogenesis of human ES cells using a co-culture method with articular chondrocytes [78]. 
Co-culture methods were also reported in presence of TGF-????? -?? [79,80]. However, the effects of 
growth factors are hardly analyzed in the co-culture method. Several growth factors, such as, FGFs, IGF, 
PDGF and Wnt, have been used for ES cell chondrogenesis without co-culture [72,81,82]. As studied in 
adult stem cell chondrogenesis, TGF-???????-?????????????????????????????????????????????????-2, -4, 
-6 and -7 also have been used [76,77,82], and combinations of TGF-??? ???? ???s enhanced the 
chondrogenic differentiation [75,81,83]. However, these are more complex, as the observed results are 
dependent on the state of differentiation of the progenitor/stem cells. Although TGF-??? ??????????
chondrogenesis in differentiated ES derived cells [79,80,84], it inhibited chondrogenesis of 
undifferentiated EBs [85]. Optimizing culture environment is another approach for ES cell 
chondrogenesis; a hypoxia condition could enhance chondrogenesis [86], and the culture of EB derived 
cells in the gel could mimic physiological condition for chondrogenesis [81,87,88]. Although ES cells are 
an attractive cell source for regenerative medicine, establishment of ES cell lines involves embryo 
destruction and is overshadowed by ethical concerns for clinical application. 
2.2.2. Induced Pluripotent Stem (iPS) Cells 
The truly exciting work in 2006 by Takahashi and Yamanaka selected 24 candidate genes that are 
highly expressed in ES cells. They introduced candidate genes into mouse fibroblasts by 
retrovirus-mediated transfections and then discovered a minimal combination of four factors (Oct3/4, 
Sox2, c-Myc and Klf4) could induce the cells to have similar properties as the ES cells. These cells have 
been christened as induced pluripotent stem (iPS) cells [89]. In 2007, generation of human iPS cells was 
reported using the same factors [90] or a set of four factors (Oct4, Sox2, Nanog, Lin28) [91]. In addition 
to mouse and human iPS cells, iPS cells from other species, such as monkey, rat, pig and equine, have 
already been established [92?95]. Important features of iPS cells are their unlimited proliferation in 
vitro, while maintaining their pluripotency and their ability of being induced by patient-specific  
cells [96]. Thus, iPS cells can supply disease or patient specific stem cells for transplantation therapy, 
drug discovery and oncology or disease pathogenesis research with minimal ethical concerns as 
compared to ES cells. The original iPS cells exhibit numerous transgene integrations due to retrovirus 
transfection and tumorigenic risk due to use of c-Myc. To reduce these risks, establishment of iPS cells 
without c-Myc [97] or using lentivirus, adenovirus or proteins [98?100] with a combination of small 
molecules, which enhance a reprogramming efficiency [101,102], have been reported. Continuous 
progress in stem cell research has been accomplished by their culture technique. ES cells and iPS cells 
used to be maintained on mouse-derived feeder cells with animal-derived serum medium. Although the 
feeder cells are inactivated via radiation or mitomycin, the potential risk of contamination of active mouse 
fibroblast or zoonotic infection cannot be denied. To avoid these risks, feeder cell- and serum-free culture 
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were established for ES cells [103,104] and applied to iPS cell culture [105,106]. Thus, these technical 
refinements might lead to safer and more efficient clinical use of iPS cells.  
Treatments of blood, neural and cardiovascular disease models with iPS cell transplantation have 
already been reported [107?110]. Compared to these fields, the research for AC regeneration using iPS 
cells has just begun. Teramura et al. reported mouse iPS-EB derived cells expressed surface markers 
similar to MSCs. These cells could differentiate toward cartilage using ????-3 and BMP-2 [111]. 
Treatment of EBs with all trans-????????? ????? ????????? ??? ????-3 and BMP-2 could also induce 
chondrogenesis [112]. Regarding human iPS cells, neural stem-cell-derived iPS cell showed 
chondrogenic potential after EB formation [113]. While in these reports the EB formation method was 
used, Liu et al. reported MSC derivation and chondrogenesis from human iPS cells without EB formation, 
culturing on thin type I collagen coated plates in presence of ROCK inhibitor Y-27632 [114]. In terms of 
disease-specific iPS cells, human OA chondrocyte-derived iPS cells have been established. They 
showed chondrogenic potential using EB formation or co-culture with chondrocytes [2,66] that 
demonstrated a potential as an alternative cell source for degenerative disease treatment. 
3. Conclusions  
Chondrogenesis using different sources of stem cells has been investigated for several years. 
However, there are still lingering questions and challenges. Tissue specific MSCs are widely studied; 
however, their reactions to growth factors vary from tissue to tissue. Even though adult stem cells are 
isolated from the same tissue, their proliferative rate or differentiation potential vary from patient to 
patient. Thus, there is still uncertainty about the MSC characteristics. Since these adult stem cells are 
heterogeneous populations, several surface markers can be used to sort these populations. Standardizing 
cell isolation and sorting might be useful to analyze the variation between tissue specific stem cells or 
between patients. ES cells are more proliferative compared to adult stem cells. However, their high 
proliferative rates have potential oncogenic concerns after transplantation into the recipients. In 
conclusion, the analysis and optimization of morphogens, such as BMPs and growth factors at each 
differentiation step, are key to the successful AC regeneration using stem cells. 
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